Novo seeks EU, U.S. approval for liraglutide for obesity

Novo Nordisk A/S (CSE:NVO; NYSE:NVO) submitted an NDA to FDA and an MAA to EMA for a 3 mg dose of liraglutide as adjunct to diet and exercise for chronic weight management in adults with obesity or wh...